China NMPA Drug Inspection - Overseas Pharmaceutical (Huadian) Co., Ltd. - Belladonna slices

On July 2, 2018, the Tianjin Municipal Market and Quality Supervision and Management Commission announced the findings of drug supervision and sampling inspections, revealing several substandard products. Inspections, conducted by various bodies including the Ninghe District Food and Drug Inspection Institute, identified quality issues with drugs from multiple manufacturers. Tianjin Zhongtian Pharmaceutical Co., Ltd.'s Pudilan Anti-inflammatory Tablets (batch ZT110255) were found substandard due to weight differences, violating the National Medical Products Administration Standard WS 3-B-0649-2002. Tianjin Municipal Public Security Hospital's Boric Acid Glycerin Ear Drops (batch 20180402) were unqualified based on their pH value, failing to meet the "Tianjin Municipal Medical Institution Preparation Standards" 2016 Edition. Furthermore, Overseas Pharmaceutical (Huadian) Co., Ltd.'s Belladonna Tablets (batch 20170901) were deemed unqualified due to appearance and weight variation, contrary to the "Chinese Pharmacopoeia" 2015 Edition, Part I. In response, municipal market supervision and law enforcement departments are investigating and addressing these issues according to applicable laws, reinforcing the regulatory commitment to public drug safety.